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Abstract
Background Genetic predictors for treatment response could optimize allocation of biological treatment in patients
with psoriasis. There is minimal knowledge about pharmacogenetics of anti-IL-17 agents.
Objectives To assess whether genetic variants in the protein-coding region or untranslated regions of the IL-17A gene
are associated with response to IL-17A inhibitors in patients with psoriasis.
Methods This was a multicenter European cohort study investigating pharmacogenetics of IL-17A inhibitors in patients
with psoriasis. Patients with plaque psoriasis treated with secukinumab or ixekizumab in daily practice were included.
For all participants, the protein-coding region and untranslated regions of the IL-17A gene were analysed using Sanger
sequencing. Identified genetic variants were tested for association with response to secukinumab/ixekizumab, measured
as ΔPASI, after 12 weeks (primary outcome) and after 24 weeks (secondary outcome). Association was tested using a
linear regression model with correction for baseline PASI as a fixed covariate and for biological naivety and body mass
index as additional covariates.
Results In total, 134 patients treated with secukinumab or ixekizumab were included. Genotyping of the cohort identi-
fied genetic variants present in untranslated regions and intronic DNA, but not in the protein-coding region of the IL-17A
gene. Five genetic variants in non-coding DNA with a known or suspected functional effect on IL-17A expression were
selected for association analyses: rs2275913, rs8193037, rs3819025, rs7747909 and rs3748067. After 12 weeks, 62%
of patients achieved PASI75 and 39% achieved PASI90. At week 24, PASI75 and PASI90 response rates were 72% and
62%, respectively. No associations were found between the five genetic variants and ΔPASI, PASI75 or PASI90 after 12
and 24 weeks of anti-IL-17A treatment.
Conclusions Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in
the protein-coding and untranslated regions of the IL-17A gene. Pharmacogenetics of IL-17A inhibitors in the treatment
of psoriasis requires further exploration.
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Introduction
Psoriasis vulgaris is a chronic, immune-mediated skin disease
with an estimated prevalence of 2% in Europe and the United
States.1 For patients with moderate-to-severe disease, systemic
therapy is often indicated.2 Biologicals are systemic agents tar-
geting specific cytokines involved in psoriasis pathogenesis.
Nowadays, a variety of biological therapies are available for pso-
riasis patients. These agents are potentially highly effective3;
however, treatment costs are considerable and the response is
variable between patients. Finding biomarkers to predict treat-
ment response is therefore high on the research agenda.
Genetic variants may explain part of the observed variability
in treatment response and serve as biomarkers for treatment suc-
cess, a field known as pharmacogenetics.4 For psoriasis, pharma-
cogenetics research of the last decade has mostly focused on
identification of genetic markers predicting response to the vari-
ous biological agents. In a systematic review on this topic, we
found that current knowledge is limited mainly to TNF blockers
(etanercept, infliximab, adalimumab) and the IL-12/23 inhibitor
ustekinumab.5 A newer class of biologicals, targeting the IL-17
cytokine, became available for treatment of plaque psoriasis in
2015. Agents within this class are secukinumab and ixekizumab
(both IL-17A inhibitors) and brodalumab (an IL-17-receptor
blocker).6–8 Studies investigating pharmacogenetics of IL-17
inhibitors are scarce. Recently, Costanzo et al.9 published results
of the SUPREME study, investigating the effect of HLA-C*06:02
status in patients treated with the IL-17A inhibitor secukinumab
in a trial setting. They found no influence of HLA-C*06:02 status
on PASI90 response rates after 16 weeks of treatment.9 Likewise,
Anzengruber et al.10 found that HLA-C*06:02 status did not
influence response to secukinumab in a small cohort of psoriasis
patients treated in daily practice. Additional studies on this topic
are needed to move a step closer towards genetics-based treat-
ment allocation in psoriasis.
Secukinumab and ixekizumab are monoclonal antibodies tar-
geting IL-17A, with ixekizumab also binding to the heterodimer
form of the protein (IL-17A/F).6,7 We hypothesized that genetic
variants in the protein-coding and surrounding regions of the
IL-17A gene could lead to changes in expression or function of
the IL-17A protein, influencing effectiveness of IL-17A inhibit-
ing drugs. To investigate this hypothesis, we sequenced the pro-
tein-coding region and untranslated regions important for the
expression of the IL-17A gene, in patients with psoriasis treated
with secukinumab or ixekizumab in daily practice. Identified
genetic variants were tested for association with treatment
response at 12 and 24 weeks.
Materials and methods
We performed a multicentre study, investigating association
between genetic variants in the IL-17A gene and clinical response
to IL-17A inhibitors in patients with psoriasis. Data were pro-
vided by four European university hospitals: Radboud Univer-
sity Medical Centre (Radboudumc) in Nijmegen, the
Netherlands; University Hospital Ghent in Ghent, Belgium;
University of Rome Tor Vergata in Rome, Italy; and University
of Tartu in Tartu, Estonia. This study was approved by the local
ethics committee of the Radboudumc. All participants gave
informed consent.
Patients
Patients with plaque psoriasis who were treated with secuk-
inumab or ixekizumab in daily practice between 2015 and 2018
were eligible for inclusion. Previous use of secukinumab or ixek-
izumab in a clinical trial was considered an exclusion criterion.
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Patients who were treated with an IL-17A inhibitor primarily for
psoriatic arthritis were also excluded.
Data collection
Venous blood for genotyping was collected in ethylenedi-
aminetriacetic acid (EDTA) tubes and stored below 70°C.
Clinical data were collected anonymously from all participat-
ing centres using Castor EDC.11 Collected data included base-
line demographics, treatment received and Psoriasis Area and
Severity Index (PASI) scores during the first 6 months of
treatment.
DNA extraction and genotyping
DNA was extracted from whole blood using standard methods
(e.g. QIAamp DNA Blood Midi Kit from Qiagen, Hilden, Ger-
many). DNA quality and integrity were checked before geno-
typing. Primers were designed to capture all three exons of the
IL-17A gene, including a margin of 20 base pairs from both the
intron–exon and exon–intron junctions. For the first exon, a
longer upstream sequence from the intron–exon junction was
chosen (200 base pairs) to also capture rs2275913 – a SNP with
known functional effects on IL-17A gene expression12–16 that
has been associated with various autoimmune diseases,17 and
also with clinical response to TNF blockers in some of these
diseases.18,19 Forward and reverse primer sequences are shown
in Table S1. Genomic DNA (10 ng) was amplified using
AmpliTaq Gold 360 Master Mix (Applied Biosystems, Foster
City, California, United States), with 0.3 lmol/L forward and
the same amount of reverse primer. PCR amplification was per-
formed using an annealing temperature of 57°C. PCR products
were purified with FastAP Thermosensitive Alkaline Phos-
phatase and Exonuclease I (Thermo Fisher Scientific, Waltham,
MA, USA) and the IL-17A gene was Sanger sequenced, using
the PCR primers described previously. Sequence results were
analysed using Vector NTI software from Thermo Fisher Scien-
tific.
Statistical analyses
For the pharmacogenetics analyses, all variants found in protein-
coding regions of IL-17A were included. For variants found in
non-coding regions, only those with a known or suspected func-
tional effect were included for further analyses. Hardy–Weinberg
equilibrium was evaluated using chi-square tests.
For all included variants, association with clinical response to
the IL-17A inhibitor (secukinumab or ixekizumab) was assessed.
Clinical response was measured by absolute changes in PASI
scores compared to baseline (ΔPASI) at two time points: after
12 weeks (primary outcome) and after 24 weeks (secondary out-
come). PASI scores for week 12 and week 24 were obtained by
interpolating between scores of the most nearby visits, using a
maximum of 180 days between two PASI measures to allow
interpolation. When interpolation was not possible, PASI
measurements made within 30 days of the week 12 or week 24
time point were used. When no nearby measurement was avail-
able either, the follow-up PASI was recorded as missing.
Influence of genetic variants on ΔPASI was evaluated by sin-
gle-variant testing, using a linear regression model with correc-
tion for baseline PASI. Additional analyses were performed
correcting not only for baseline PASI as a fixed covariate, but
for other possible covariates as well. For covariate selection, we
performed univariate linear regression analysis for a variety of
baseline and treatment characteristics (Table S2). Variables
with a P-value below 0.05 in univariate analysis were consid-
ered for further testing. We then tested these variants for their
independent association with ΔPASI using a backward stepwise
regression model. Variables that remained independently asso-
ciated with clinical response in this multivariate model were
considered relevant covariates and thus corrected for in the
additional analyses. As a supplementary analysis, we also tested
for association between genetic variants and achievement of
PASI75 and PASI90 after 12 and 24 weeks using binary logistic
regression models.
All tests were performed under assumption of an additive
genetic model. A Bonferroni-adjusted P-value cut-off was used
to correct for the total number of genetic variants tested. Analy-
ses were performed in PLINK version 1.9.20
Results
Baseline demographics
We included 134 patients treated with either secukinumab or
ixekizumab from four European university hospitals (Table 1).
The majority of patients were treated with secukinumab (88%).
Mean age at start of anti-IL-17A therapy was 44.7 years (SD
13.9) and 92 patients were male (69%). Median baseline PASI
was 11.4 (range 2.1–56.7). Mean BMI was 28.6 kg/m2 (SD 5.3).
Twenty-nine patients (22%) had a confirmed diagnosis of pso-
riatic arthritis. Sixty patients (45%) were naive for biologics at
start of anti-IL-17A therapy. Comparison of baseline demo-
graphics across the four centres showed differences with respect
to baseline PASI (higher in Italy and Estonia), prevalence of
psoriatic arthritis (higher in the Netherlands and Italy) and
with respect to previous treatments received (higher number of
prior conventional systemics and prior biologics in the Nether-
lands).
Genotyping results
Sequencing of the IL-17A exons in the present cohort led to the
identification of eight known genetic variants: rs2275913,
rs8193037, rs3819025, rs7747909, rs181990814, rs551634550,
rs1974226 and rs3748067. None of the identified variants
were in the protein-coding region (Table 2). A known or sus-
pected functional effect on IL-17A gene expression was described
for rs2275913,12–16 rs8193037,21 rs3819025,22 rs7747909,23
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rs3748067,12 and these variants were therefore selected for fur-
ther analysis (Table 2). All selected genetic variants were in
Hardy–Weinberg equilibrium.
Response results
PASI follow-up scores were available for 133 patients at week 12
(primary outcome) and for 109 patients at week 24 (secondary
outcome). Reasons for missing values at week 24 were as follows:
measurement not done (n = 12), limited follow-up period
(n = 8), treatment discontinued within 24 weeks due to side-ef-
fects (n = 4) or due to inefficacy (n = 1). Median ΔPASI was
9.8 [range 53.5 to 2.7] at week 12 and 10.0 [range 54.1 to
3.8] at week 24. Median absolute PASI values were 2.3 [range 0
to 30.0] at week 12 and 0.8 [range 0 to 50.5] at week 24. PASI75,
PASI90 and PASI100 were achieved in respectively 62%, 39%
and 18% of patients after 12 weeks and in 72%, 62% and 28%
after 24 weeks. PASI75, PASI90 and PASI100 response rates per
SNP genotype are shown in Table S3.
Pharmacogenetic analyses
Influence of genetic variants on ΔPASI at week 12 and 24 In
the primary analyses, we tested for association between genetic
variants and ΔPASI (corrected for baseline PASI) at week 12.
None of the five investigated genetic variants were associated
with anti-IL-17A response after 12 weeks (Table 3). For addi-
tional covariate correction, we selected prior biological use (bio-
logical naivety) and body mass index (BMI) as relevant
covariates, based on statistical approaches described previously
(Table S2). Biological naivety and a lower body mass index have
also shown to be associated with higher effectiveness of biologi-
cals in previous daily practice studies.24–27 Additional covariate
correction for biological naivety and BMI did not change the
outcomes of our analyses (Table S4). For the 24 weeks outcome,
no associations between genetic variants and ΔPASI were found
either (Table 3, Table S4).
Influence of genetic variants on PASI75 and PASI90 response
at weeks 12 and 24 Using binary logistic regression, we tested
the influence of genetic variants on achievement of PASI75 and
PASI90 after 12 and 24 weeks, again with covariate corrections.
No significant associations were discovered (Tables S5 and S6).
Discussion
We investigated pharmacogenetics of anti-IL-17A treatment in
patients with psoriasis, using a candidate gene approach focused
on the protein-coding region of the IL-17A gene and surround-
ing regions important for IL-17A expression. A sequencing











Sex (male), n (%) 27 (60) 21 (68) 36 (75) 8 (80) 92 (69)
Ethnicity (Caucasian), n (%) 38 (84) 31 (100) 48 (100) 10 (100) 127 (95)
Age at start of anti-IL-17A therapy, years, mean  SD 45.0  13.6 49.0  14.2 42.3  13.9 41.5  12.4 44.7  13.9
Age at onset of psoriasis, years, median [range] 18 [5–58] 26 [3–70] 21.5 [3–62] 20.5 [13–37] 22 [3–70]
Disease duration, years, median [range] 20 [2–45] 19 [3–47] 16 [0–55] 22.5 [4–31] 18 [0–55]
Psoriatic arthritis† (yes), n (%)† 18 (40) 4 (13) 3 (6) 4 (40) 29 (22)
Weight, kg, mean  SD 94.3  18.9 83.8  14.0 80.9  14.9 92.7  23.2 86.8  17.7
BMI, kg/m2, mean  SD 30.4  5.9 28.1  4.7 27.2  5.0 28.7  4.8 28.6  5.3
Baseline PASI, median [range] 9.4 [2.1–40.7] 11.9 [3.0–36.2] 14.7 [8.0–56.7] 21.1 [10.9–36.6] 11.4 [2.1–56.7]
Baseline PASI, mean  SD 9.8  6.5 12.7  5.9 20.3  12.8 23.0  8.9 15.2  10.5
Prior biological use (yes), n (%) 43 (96) 12 (39) 13 (27) 6 (60) 74 (55)
Biologics before anti-IL-17A therapy, n, median [range] 3 [0–7] 0 [0–3] 0 [0–5] 1 [0–1] 1 [0–7]
0 prior biologics, n (%) 2 (4) 19 (61) 35 (73) 4 (40) 60 (45)
1 prior biologics, n (%) 11 (24) 5 (16) 3 (6) 6 (60) 25 (19)
2 prior biologics, n (%) 3 (7) 5 (16) 7 (15) – 15 (11)
3 prior biologics, n (%) 13 (31) 2 (7) 1 (2) – 17 (13)
4 prior biologics, n (%) 12 (27) – 1 (2) – 13 (10)
≥5 prior biologics, n (%) 3 (7) – 1 (2) – 4 (3)
Prior conventional/other systemics use (yes), n (%) 44 (98) 31 (100) 44 (92) 10 (100) 129 (96)
Conventional/other systemics‡ before anti-IL-17 therapy, n,
median [range]
3 [0–4] 2 [1–4] 1 [0–3] 2 [1–3] 2 [0–4]
†Percentage based on patients with a diagnosis of psoriatic arthritis as confirmed by a rheumatologist.
‡Conventional and ‘other’ systemics registered included the following: methotrexate, cyclosporine, retinoids (acitretin or etretinate), fumaric acid esters and
apremilast.
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approach was chosen to allow for potential rare variants to be
detected as well. In this multicentre, European cohort of psoria-
sis patients treated with secukinumab or ixekizumab in daily
practice, we were unable to detect genetic variants in the pro-
tein-coding region of the IL-17A gene. Five common variants in
the non-coding DNA of IL-17A with possible functional effects
were identified, but showed no association with response to IL-
17A inhibitors.
Our main finding is that we did not find any variants,
common or rare, in the protein-coding region of IL-17A in
our cohort of 134 psoriasis patients. However, sequencing did
identify variants in the periphery of the coding DNA, present
in untranslated regions or introns. Out of all variants identi-
fied in these regions, we selected only those with a suspected
functional effect based on previous research: rs2275913,
rs8193037, rs3819025, rs7747909 and rs3748067 (Table 2).
The five selected variants were tested for association with clin-
ical response to IL-17A inhibitors secukinumab and ixek-
izumab after 12 and 24 weeks, using different outcome
measures for clinical response (ΔPASI, PASI75, PASI90) with
correction for relevant covariates. We found no associations
between the genetic variants and response to anti-IL-17A ther-
apy (Table 3, Tables S4–S6).
This is one of the first explorations of pharmacogenetics of
the IL-17-class biologicals in psoriasis. Costanzo et al.9 evaluated
the influence of HLA-C*06:02 status on efficacy and safety of
secukinumab in a phase III clinical trial of patients with moder-
ate-to-severe psoriasis (SUPREME study). They observed no dif-
ferences in PASI90 response after 16 weeks of treatment between
HLA-C*06:02 positive and negative patients.9 Similarly, in a
small psoriasis cohort treated with secukinumab in daily prac-
tice, Anzengruber et al. found that PASI improvement after
12 weeks did not differ between HLA-C*06:02 positive and







MAF Genotypes (n) Functional relevance of minor allele Selected
for
analyses
rs2275913 g.52186235 5’ UTR G>A 0.3534 GG/GA/AA : 58/56/19‡ • Increased IL-17 production in
AMD12/HC12,13; increased IL-17
serum levels in VM14; decreased
IL-17 serum levels in chronic
HBV infection/HC15 and in IS16
Yes
rs8193037 g.52186311 5’ UTR G>A 0.0187 GG/GA/AA : 129/5/0 • Increased IL-17 production in
NSCLC/HC21
Yes
rs3819025 g.52186476 Intron G>A 0.0709 GG/GA/AA : 116/17/1 • Decreased IL-17 serum levels in
BC/HC22
Yes
rs7747909 g.52189451 3’ UTR G>A 0.2276 GG/GA/AA : 79/49/6 • Decreased microRNA binding,
leading to increased IL-17
production in AMD23
Yes
rs181990814 g.52189958 3’ UTR C>A 0.0037 CC/CA/AA : 133/1/0 • Not described/unknown No
rs551634550 g.52190171 3’ UTR G>A 0.0037 GG/GA/AA : 133/1/0 • Not described/unknown No
rs1974226 g.52190537 3’ UTR C>T 0.1604 CC/CT/TT : 92/41/1 • Not described/unknown No
rs3748067 g.52190541 3’ UTR C>T 0.1082 CC/CT/TT : 108/23/3 • Increased IL-17 production in AMD12 Yes
†Based on reference sequence built GRCh38.p12.
‡One missing genotype for this genetic variant.
AMD, age-related macular degeneration; BC, breast cancer; HBV, hepatitis B virus; HC, healthy controls; IS, ischaemic stroke; MAF, minor allele frequency
(in this cohort); NSCLC, non-small-cell lung cancer; UTR, untranslated region.
Table 3 Linear regression analyses for association between IL-
17A polymorphisms and ΔPASI after 12 and 24 weeks of anti-IL-
17 treatment, corrected for baseline PASI
Genetic
variant
n Allele Beta 95% CI P-value
Week 12
rs2275913 132 A 0.2659 1.119, 0.5873 0.5424
G Ref
rs8193037 133 A 1.292 1.829, 4.414 0.4186
G Ref
rs3819025 133 A 0.03737 1.632, 1.557 0.9634
G Ref
rs7747909 133 A 0.2668 0.7545, 1.288 0.6095
G Ref
rs3748067 133 T 0.1327 1.149, 1.414 0.8395
C Ref
Week 24
rs2275913 109 A 0.008133 1.459, 1.475 0.9914
G Ref
rs8193037 109 A 0.8671 5.41, 7.145 0.7871
G Ref
rs3819025 109 A 0.2242 3.035, 2.587 0.8761
G Ref
rs7747909 109 A 1.072 0.6787, 2.822 0.2328
G Ref
rs3748067 109 T 1.252 3.38, 0.8752 0.2512
C Ref
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negative patients.10 To our knowledge, we are the first to system-
atically investigate pharmacogenetics of the IL-17A gene in a
large, multicentre daily practice cohort of psoriasis patients trea-
ted with secukinumab and ixekizumab.
The present study has several strengths, as well as limitations.
This is one the first explorations of pharmacogenetics of IL-17A
inhibitors in patients with psoriasis. Using a sequencing
approach allowed us to look at the complete coding region of
IL-17A, rather than focusing solely on common variants using a
SNP-based approach. Potential rare variants, for example rare
variants in IL-17A that are specifically present in the psoriasis
population, could have been detected this way as well. Our main
limitation is a small cohort size, reducing the chance of finding
very rare genetic variants and reducing the power to detect small
genetic effects on treatment response. However, very rare vari-
ants and very small genetic effects may also be less of interest for
the clinical setting, because of their limited usefulness in patient
care.
In general, pharmacogenetic studies of biological treatment
in psoriasis have thus far generated conflicting and inconclu-
sive results,5 with the exception of HLA-C*06:02 which showed
to be associated with response to ustekinumab in multiple large
cohorts28–30 and on a meta-analytic level.31 In rheumatoid
arthritis (RA), response to anti-TNF agents is estimated to be
explained by genetic factors for 18–87%, depending on outcome
definitions and analytic methods used.32,33 Regardless, genome-
wide association studies (GWAS) in RA patients have not
uncovered SNPs associated with anti-TNF response on a geno-
mewide significance level.34–38 This might indicate that heri-
tability of response to biologicals in RA is highly polygenic, with
large numbers of variants involved in the outcome, each con-
tributing a small effect.33 For psoriasis, estimations of heritabil-
ity of biological response are not available, and large GWAS
data are lacking. However, underlying genetic structures regard-
ing response to these drugs in psoriasis patients might very well
resemble those in RA. Detecting numerous genetic loci with
small genetic effects will require extensive sample sizes, indicat-
ing that international consortia will be indispensable in resolv-
ing pharmacogenetics of biological treatment.
In summary, we found that the protein-coding region of the
IL-17A gene is invariable, with no genetic variants discovered in
this region amongst 134 patients with psoriasis. A selection of
five variants from non-coding regions was evaluated with
regards to anti-IL-17A treatment response, but no associations
were found. Based on these findings, we conclude that variability
in response to IL-17A inhibitors cannot be explained by varia-
tion in the protein-coding and untranslated regions of the IL-
17A gene. Pharmacogenetics of IL-17A inhibitors in the treat-
ment of patients with psoriasis remains to be elucidated, which
may be dependent on large scale, non-hypothesis driven genetic
association studies.
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